Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Inclusion Criteria * Has Candidemia or invasive candidiasis documented by typical clinical signs and symptoms and confirmed by fungal culture or histologic confirmation Exclusion Criteria * Has abnormal liver test parameters, e.g., AST or ALT \> 10 times upper limit of normal * Has life expectancy judged to be less than 5 days * De novo patients who have received a systemic antifungal agent for the treatment of this episode of candidemia or invasive candidiasis for more than 48 hours prior to the first dose of FK463; or efficacy failure patients who have received =\< 5 days of prior systemic antifungal therapy for the treatment of this episode of candidemia or invasive candidiasis * Require treatment with topical or systemic antifungal agents for conditions other than candidemia or invasive candidiasis